Advertisement
Zhejiang Hisun Pharmaceutical Full Year 2024 Earnings: Revenues Beat Expectations
Zhejiang Hisun Pharmaceutical (SHSE:600267) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥9.79b (down 5.7% from FY 2023).
- Net income: CN¥601.2m (up from CN¥93.2m loss in FY 2023).
- Profit margin: 6.1% (up from net loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zhejiang Hisun Pharmaceutical Revenues Beat Expectations
Revenue exceeded analyst estimates by 3.2%.
Looking ahead, revenue is forecast to grow 1.9% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are up 9.5% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 2 warning signs for Zhejiang Hisun Pharmaceutical (1 makes us a bit uncomfortable!) that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if Zhejiang Hisun Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:600267
Zhejiang Hisun Pharmaceutical
Engages in the research, development, production, and sale of biological and generic drugs in China.
Undervalued with excellent balance sheet and pays a dividend.
Market Insights
Advertisement
Weekly Picks
ST
stuart_roberts on Unicycive Therapeutics ·
Looking to be second time lucky with a game-changing new product
Fair Value:US$21.5371.1% undervalued
33 followersusers have followed this narrative
0 commentsusers have commented on this narrative
5 likesusers have liked this narrative
HE
HegelBayeBagel on PlaySide Studios ·
PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade
Fair Value:AU$0.8463.1% undervalued
9 followersusers have followed this narrative
2 commentsusers have commented on this narrative
5 likesusers have liked this narrative
AN
AnimalDoctorKwon on Inotiv ·
Inotiv NAMs Test Center
Fair Value:US$1.275.7% undervalued
19 followersusers have followed this narrative
2 commentsusers have commented on this narrative
5 likesusers have liked this narrative
TH
TheValueDetector on Cognyte Software ·
This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti
Fair Value:US$95.6792.6% undervalued
23 followersusers have followed this narrative
2 commentsusers have commented on this narrative
4 likesusers have liked this narrative
Recently Updated Narratives
CA
Canderous on PetroTal ·
Beyond 2026, Beyond a Double
Fair Value:CA$1.8178.2% undervalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AG
Agricola on 1911 Gold ·
A case for TSXV:AUMB to reach USD$2.69 (CAD$3.70) by 2030 (15X).
Fair Value:CA$3.774.9% undervalued
19 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
CO
composite32 on Freehold Royalties ·
Freehold: Offers a fantastic growth-income intersection up to $50 WTI. Below $50 WTI, it may offer historic opportunities in terms of ROI.
Fair Value:CA$19.3811.9% undervalued
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.4% undervalued
59 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
AN
AnalystConsensusTarget on Microsoft ·
Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
Fair Value:US$59633.4% undervalued
1279 followersusers have followed this narrative
2 commentsusers have commented on this narrative
9 likesusers have liked this narrative
TA
Talos on Tesla ·
The "Physical AI" Monopoly – A New Industrial Revolution
Fair Value:US$665.3638.3% undervalued
45 followersusers have followed this narrative
19 commentsusers have commented on this narrative
22 likesusers have liked this narrative
Trending Discussion
TI
TickerTickle on Figma ·
Figma is still deeply embedded as the default design system in big companies, and the ecosystem (Buzz, Slides, Sites, Make) is clearly the strategic play rather than a one‑off product bet. None of those qualitative assumptions have really broken yet, the bigger change has been sentiment toward growth/AI software in general, not Figma’s product reality. Assuming ~30% annual growth, margins stepping up to 25%, and a 40x PE in 2030 with an 8.4% discount rate is too optimistic now considering how the broader market is now pricing similar SaaS names, which means you can believe in the long term thesis and still accept that the stock might chop sideways or even drift lower while expectations and multiples reset. I will be sharing an update soon.
1
|0
TH
TheValueDetector on Cognyte Software ·
CEO comp looks high on the surface, but context matters. Cognyte is approaching profitability — losses narrowed 23% YoY and they’re now guiding positive adjusted EBITDA of $47M for FY26. Revenue is growing 12-14% annually with a debt-free balance sheet. The board is compensating for execution on a turnaround, not rewarding stagnation. If they hit their $500M revenue / 20%+ EBITDA margin target by FY28, today’s comp will look like a bargain in hindsight. Imagine if everyone that has invested in Tesla 10 years ago had the same mentality...
0
|0
TH
TheInvestingFool on PlaySide Studios ·
Looks interesting, I am jumping into the finances now. Your 15% margin seems high for a conservative model, can't just ignore the years they need to invest. You didnt seem to mention that they had to dilute the sharebase by issuing ~40mil shares. raising ~8 mil. should be enough if mouse does OK. If not they will need to raise more to suvive. Losing 20m a year, 14m after there 6m cutbacks. Am I reading it right that they have no debt. have they any history of raising debt? First look it is too dependant on the mouse and GoT games. they do well stock will 2-3x, poorly and it will drop. I am not sure I agree with your work for hire backstop. Unlikely meta horizons will continue with the same size contract going forward. say 10% margins and 15x multiple on 30m. that is 45m, which with the new sharecount is 10c. It is a backstop but maybe not that strong. Mouse fails and devs could start jumping ship and outside contracts could dry up. Hmm on top of all that AI could be disrupting the work for hire model. I think I have mostly talked myself out of it. Although Mouse looks good and does seem like the type of game that could go viral on twitch for a few months. If it does you will likly get a great return 5x plus. crap maybe I am talking myself back in.
0
|0